Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02773030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02773030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 14, 2016
Completion date
July 28, 2028
Enrollment
466 (actual)
Sites
162

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma